External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort
Standard
External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort. / Tilki, Derya; Mandel, Philipp; Schlomm, Thorsten; Chun, Felix K-H; Tennstedt, Pierre; Pehrke, Dirk; Haese, Alexander; Huland, Hartwig; Graefen, Markus; Salomon, Georg.
In: J UROLOGY, Vol. 193, No. 6, 01.06.2015, p. 1970-1975.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort
AU - Tilki, Derya
AU - Mandel, Philipp
AU - Schlomm, Thorsten
AU - Chun, Felix K-H
AU - Tennstedt, Pierre
AU - Pehrke, Dirk
AU - Haese, Alexander
AU - Huland, Hartwig
AU - Graefen, Markus
AU - Salomon, Georg
N1 - Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - PURPOSE: The Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) score predicts prostate cancer (PCa) recurrence based on pathologic information from radical prostatectomy (RP). CAPRA-S has never been externally validated in a European cohort. We independently validated the CAPRA-S in a European, single-institution database.MATERIALS AND METHODS: The study cohort comprised of 14532 patients treated with radical prostatectomy between January 1992 and August 2012. Prediction of biochemical recurrence (BCR), metastasis and cancer-specific mortality (CSM) by CAPRA-S was assessed by Kaplan-Meier analysis and the c-index. Performance of CAPRA-S in predicting BCR was assessed by calibration plot and decision curve analysis.RESULTS: Median follow up was 50.8 months (IQR 25.0 - 96.0). BCR occurred in 20.3% of men at a median time of 21.2 mo (IQR 7.7 - 44.9). When stratifying patients by CAPRA-S risk groups, BCR-free survival estimates at 5 years were 91.4%, 70.4%, and 29.3% for the low, intermediate and high-risk group, respectively. The c-index for CAPRA-S in predicting BCR was 0.80. The c-indices for CAPRA-S in predicting metastasis and CSM were 0.85 and 0.88, respectively. 417 men developed metastasis, and 196 men died from PCa.CONCLUSIONS: The postoperative CAPRA-S score was accurate when applied in a European study cohort and predicted biochemical recurrence, metastasis and CSM after RP with c-indices > 0.80. The score can be valuable for decision-making for adjuvant therapy.
AB - PURPOSE: The Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) score predicts prostate cancer (PCa) recurrence based on pathologic information from radical prostatectomy (RP). CAPRA-S has never been externally validated in a European cohort. We independently validated the CAPRA-S in a European, single-institution database.MATERIALS AND METHODS: The study cohort comprised of 14532 patients treated with radical prostatectomy between January 1992 and August 2012. Prediction of biochemical recurrence (BCR), metastasis and cancer-specific mortality (CSM) by CAPRA-S was assessed by Kaplan-Meier analysis and the c-index. Performance of CAPRA-S in predicting BCR was assessed by calibration plot and decision curve analysis.RESULTS: Median follow up was 50.8 months (IQR 25.0 - 96.0). BCR occurred in 20.3% of men at a median time of 21.2 mo (IQR 7.7 - 44.9). When stratifying patients by CAPRA-S risk groups, BCR-free survival estimates at 5 years were 91.4%, 70.4%, and 29.3% for the low, intermediate and high-risk group, respectively. The c-index for CAPRA-S in predicting BCR was 0.80. The c-indices for CAPRA-S in predicting metastasis and CSM were 0.85 and 0.88, respectively. 417 men developed metastasis, and 196 men died from PCa.CONCLUSIONS: The postoperative CAPRA-S score was accurate when applied in a European study cohort and predicted biochemical recurrence, metastasis and CSM after RP with c-indices > 0.80. The score can be valuable for decision-making for adjuvant therapy.
U2 - 10.1016/j.juro.2014.12.020
DO - 10.1016/j.juro.2014.12.020
M3 - SCORING: Journal article
C2 - 25498570
VL - 193
SP - 1970
EP - 1975
JO - J UROLOGY
JF - J UROLOGY
SN - 0022-5347
IS - 6
ER -